Medtronic DBS therapy For Parkinson's disease

Alert Indications, Safety, and Warnings

DBS for Parkinson's
fact sheet

Learn more about treatment options, expected results, and why DBS therapy is an important addition to the treatment continuum for Parkinson’s disease.

Download fact sheet

Treating the symptoms of Parkinson's

Deep brain stimulation (DBS) from Medtronic safely and effectively manages tremor, rigidity, and bradykinesia associated with Parkinson's disease.1 It may be a therapeutic option for patients with recent or longer-standing motor complications.

Benefits of Medtronic DBS

Helps control motor function and improves quality of life

  • Improves motor function and reduce medication for patients with recent or longer-standing motor complications1,2
  • Improves quality of life and activities of daily living for Parkinson’s patients with recent or longer-standing onset of motor complications.1,2
  • Reduces medication and improves drug-related complications1
  • Offers the first safe* access to MRI anywhere on the body for diagnosing health conditions in patients with deep brain stimulation
  • Allows therapy to be turned off or reversed, preserving options for future therapies and treatments

Risks

Physicians should be aware that the risks associated with initial surgery may increase with clinical conditions such as:

  • Stroke or neurological disorders other than idiopathic Parkinson’s disease
  • Cardiovascular disease
  • Renal or hepatic failure
  • Diabetes mellitus

To help ensure maximum benefits from the neurostimulation system, long-term, post-surgical management of patients is recommended.

The use of Medtronic DBS therapy for Parkinson’s disease has been studied in 5 large randomized control trials. Download our clinical summary to see the data.

Download clinical summary

Is your patient a candidate for DBS therapy?

Consider deep brain stimulation when a patient has:

  • Symptoms of levodopa-responsive Parkinson's disease of at least 4 years' duration that are not adequately controlled with medication.
  • And motor complications of recent onset (from 4 months to 3 years) or motor complications of longer-standing duration.

The safety and effectiveness of this therapy has not been established for the following:

  • Patients with neurological disease origins other than idiopathic Parkinson’s disease
  • Patients with a previous surgical ablation procedure
  • Patients who are pregnant
  • Patients under the age of 18 years
  • Patients with dementia
  • Patients with coagulopathies
  • Patients with moderate to severe depression

Medtronic Academy

Access on-demand DBS resources, procedural videos, webinars, and more at Medtronic Academy.

Log in to academy

Contact Medtronic

Reach U.S. clinician services for Medtronic DBS products at:

800-328-0810

 

*

Medtronic DBS systems are MR Conditional and safe in the MR environment as long as certain conditions are met. If the conditions are not met, a significant risk is tissue lesions from component heating, especially at the lead electrodes, resulting in serious and permanent injury including coma, paralysis, or death. Refer to the MRI Guidelines for Medtronic Deep Brain Stimulation Systems at www.medtronic.com/mri or contact Medtronic at (1-800) 328-0810 for a complete list of conditions. Also review current MRI manufacturer labeling before conducting the MRI. 

1

Medtronic DBS Therapy for Parkinson's Disease and Essential Tremor Clinical Summary, 2015.

2

Schuepbach WMM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med. February 14, 2013; 368:610-622.